tirzepatide is fda approved Wins Approval for Weight Loss Eli Lilly seeks FDA approval

The SUSTAIN-6 study demonstrated a 26% reduction in major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in high-risk patients with type 2 diabetes

Adverse clinical outcomes and discontinued programs are systematically underreported because sponsors have limited incentive to publish failed studies, and journals favor positive results

Active Ingredient Tirzepatide (Mounjaro) Inactive Ingredients Sodium chloride Sodium phosphate dibasic heptahydrate Water for injection Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH Contraindications A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO

A larger analysis of 500 type 2 diabetes patients over two years found more granular results